Related references
Note: Only part of the references are listed.Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M. Silverman et al.
CANCER DISCOVERY (2021)
Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progestin Therapy in Atypical Hyperplasia and Low-Grade Endometrial Cancer
Asmerom T. Sengal et al.
CANCERS (2021)
2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology
Richard J. Epstein et al.
JOURNAL OF ONCOLOGY (2021)
FGF9 and FGF10 activate distinct signaling pathways to direct lung epithelial specification and branching
Yongjun Yin et al.
SCIENCE SIGNALING (2020)
Integrated Analysis of Structural Variation and RNA Expression of FGFR2 and Its Splicing Modulator ESRP1 Highlight the ESRP1amp-FGFR2norm-FGFR2-IIIchigh Axis in Diffuse Gastric Cancer
Sara Pinto Teles et al.
CANCERS (2020)
FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes
Asmerom T. Sengal et al.
CLINICAL CANCER RESEARCH (2020)
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
Anne Sophie V. M. van den Heerik et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
Sung-Bae Kim et al.
TARGETED ONCOLOGY (2019)
Endometrial stem/progenitor cells and their role in the pathogenesis of endometriosis
Fiona L. Cousins et al.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2018)
BGJ398 for FGFR-altered advanced cholangiocarcinoma
Judith A. Gilbert
LANCET ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina et al.
NATURE REVIEWS CANCER (2017)
Confirmation of ProMisE: A Simple, Genomics-Based Clinical Classifier for Endometrial Cancer
Aline Talhouk et al.
CANCER (2017)
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten et al.
CLINICAL CANCER RESEARCH (2016)
Prognostic implications of epithelial to mesenchymal transition related proteins (E-cadherin, Snail) and hypoxia inducible factor 1α in endometrioid endometrial carcinoma
Nehal S. Abouhashem et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2016)
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts
Ellen Stelloo et al.
CLINICAL CANCER RESEARCH (2016)
A clinically applicable molecular-based classification for endometrial cancers
A. Talhouk et al.
BRITISH JOURNAL OF CANCER (2015)
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
Ellen Stelloo et al.
MODERN PATHOLOGY (2015)
Prognostic impact of EMT (epithelial-mesenchymal-transition)-related protein expression in endometrial cancer
Yoshimichi Tanaka et al.
CANCER BIOLOGY & THERAPY (2013)
Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas
Qi Zhao et al.
CLINICAL CANCER RESEARCH (2013)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
FGFR2 Promotes Breast Tumorigenicity through Maintenance of Breast Tumor-Initiating Cells
Sungeun Kim et al.
PLOS ONE (2013)
FGFR2 alterations in endometrial carcinoma
Sonia Gatius et al.
MODERN PATHOLOGY (2011)
The Antiproliferative Action of Progesterone in Uterine Epithelium Is Mediated by Hand2
Quanxi Li et al.
SCIENCE (2011)
Reduced Expression of Fibroblast Growth Factor Receptor 2IIIb in Hepatocellular Carcinoma Induces a More Aggressive Growth
Thomas Amann et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Epithelial-Mesenchymal Transitions in Development and Disease
Jean Paul Thiery et al.
CELL (2009)
ESRP1 and ESRP2 Are Epithelial Cell-Type-Specific Regulators of FGFR2 Splicing
Claude C. Warzecha et al.
MOLECULAR CELL (2009)
The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events
Claude C. Warzecha et al.
RNA BIOLOGY (2009)
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes
P. M. Pollock et al.
ONCOGENE (2007)
The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development
Richard Grose et al.
EMBO JOURNAL (2007)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE UROLOGY (2005)
Share Paper
